Amgen Inc. Stock News

Sustainable Insight Capital Management LLC boosted its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 5.9% during the 3rd quarter, Holdings Channel reports. The firm owned 1,816 shares of the medical research companys stock after acquiring an additional 101 shares during the quarter. Sustainable Insight Capital Management LLCs holdings in Amgen were worth $386,000 as []

Hamilton Point Investment Advisors LLC raised its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 1.0% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 30,633 shares of the medical research companys stock after purchasing an additional 313 shares during the period. Amgen accounts []

Related Stocks: RTX , CTSH , AMGN , WMT , CSCO , ANTM , IDA , PKI , BIO , AZN , ALXN , DG , GNTX , GRMN , PSX ,

Wells Fargo & Company initiated coverage on shares of Amgen (NASDAQ:AMGN) in a report issued on Wednesday, The Fly reports. The firm issued an equal weight rating and a $210.00 price target on the medical research companys stock. Other equities analysts also recently issued reports about the stock. Robert W. Baird reiterated a sell rating []

Related Stocks: MTCH , DOCU , ALC , LYFT , NFLX , HUBS , ETN , ZTS , LHX , AMGN , BABA , VMW , NUE ,

Sumitomo Life Insurance Co. trimmed its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 4.1% in the third quarter, Holdings Channel reports. The institutional investor owned 9,283 shares of the medical research companys stock after selling 393 shares during the period. Sumitomo Life Insurance Co.s holdings in Amgen were worth $1,974,000 as of its most []

DUBLIN--(BUSINESS WIRE)--The "Adalimumab, Infliximab and Etanercept Biosimilars Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com''s offering. The global adalimumab, infliximab and etanercept biosimilars market is expected to grow from $2.21 billion in 2020 to $3.02 billion in 2021 at a compound annual growth rate (CAGR) of 36.7%. The market is expected to reach $12.2 billion in 2025 at a CAGR of 42%. Major players in the adalimumab, i

Park Avenue Securities LLC grew its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 1.7% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 6,857 shares of the medical research company’s stock after purchasing an additional 114 shares during the period. Park Avenue Securities LLC’s holdings […]

The Cell and Gene Therapy Market covers the present scenario (with the base year being 2021) and the growth prospects of global Cell and Gene Therapy market for 20212028. The report discusses the key drivers influencing market growth, opportunities, the

Coherent Market Insights recently published a detailed study of Biopharmaceutical and Biomedicine Market covering interesting aspects of the market with supporting development scenarios ranging from 2021-2028. The report delivers the clean elaborated structure of the Market comprising each and every

Take a look to see if these dogs of the Dow are worth buying.

According to latest research report published by WMR, Cancer Immunotherapy industry represents facts and data using diagrams, graphs, pie charts, and other pictorial representations. This enhances the visual representation and also helps businesses in understanding the facts much better. Get

Stocks Analysis by Zacks Investment Research covering: Amgen Inc, Micron Technology Inc, United Parcel Service Inc, Visa Inc Class A. Read Zacks Investment Research''s latest article on Investing.com

Related Stocks: BK , AMGN , DUK ,

Sumitomo Mitsui Trust Holdings Inc. lowered its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 9.2% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,327,327 shares of the medical research companys stock after selling 236,723 shares during the period. Sumitomo Mitsui []